Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
US shutdown freezes new drug applications
Key FDA decisions are expected to face delays.
Takeda’s cancer prospects dim further
After trimming its cell therapy pipeline last year, the group is now out entirely.
Astra's clash of the T-cell engager Titans
The Titan CD8-guiding technology seems to have spawned a new variant.
M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
FDA red and green lights: September 2025
A single-arm trial was enough for J&J’s Inlexzo nod.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
